Ferrara, Roberto
 Distribuzione geografica
Continente #
EU - Europa 314
NA - Nord America 290
AS - Asia 179
SA - Sud America 17
AF - Africa 1
Totale 801
Nazione #
US - Stati Uniti d'America 287
RU - Federazione Russa 145
GB - Regno Unito 83
CN - Cina 76
SG - Singapore 60
IE - Irlanda 19
SE - Svezia 18
HK - Hong Kong 17
FR - Francia 13
VN - Vietnam 13
BR - Brasile 12
DE - Germania 11
IT - Italia 9
FI - Finlandia 7
CA - Canada 3
JP - Giappone 3
KR - Corea 3
NL - Olanda 3
ID - Indonesia 2
VE - Venezuela 2
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
EC - Ecuador 1
EE - Estonia 1
GA - Gabon 1
IN - India 1
LT - Lituania 1
NO - Norvegia 1
OM - Oman 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 801
Città #
Chandler 81
Southend 79
Moscow 48
Dallas 41
Woodbridge 32
Singapore 26
Dublin 19
Beijing 17
Hong Kong 17
Ashburn 16
Houston 11
New York 11
Nanjing 6
Wilmington 6
Ho Chi Minh City 5
Jinan 5
Lawrence 5
Princeton 5
Shenyang 5
Columbus 4
Los Angeles 4
The Dalles 4
Tianjin 4
Buffalo 3
Detroit 3
Hanoi 3
Montreal 3
Ningbo 3
Seoul 3
Taizhou 3
Tokyo 3
Turku 3
Augusta 2
Haikou 2
Hebei 2
Jakarta 2
London 2
Marostica 2
Meda 2
Munich 2
Redondo Beach 2
Rio de Janeiro 2
Salvador 2
Sindelfingen 2
Zhengzhou 2
Ann Arbor 1
Austin 1
Baku 1
Barquisimeto 1
Birmingham 1
Biên Hòa 1
Brooklyn 1
Chicago 1
Colombo 1
Fortaleza 1
Fremont 1
Fuzhou 1
Guangzhou 1
Guiyang 1
Ibatiba 1
Ituiutaba 1
La Guaira 1
Lancaster 1
Libreville 1
Manchester 1
Milwaukee 1
Montes Claros 1
Mumbai 1
Nanchang 1
Newark 1
Oceanside 1
Orem 1
Phoenix 1
Phú Thái 1
Portoviejo 1
Poções 1
Redwood City 1
Rosario 1
Santiago Metropolitan 1
Sarny 1
Schertz 1
Seattle 1
Seeb 1
Shanghai 1
Stavanger 1
São Paulo 1
Taiyuan 1
Tallinn 1
Tashkent 1
Thái Nguyên 1
Topeka 1
Verona 1
Vĩnh Tường 1
Warsaw 1
Washington 1
Xi'an 1
Totale 555
Nome #
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 189
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 162
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 160
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 152
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 145
Totale 808
Categoria #
all - tutte 2.557
article - articoli 2.557
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.114


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 3 1
2021/202243 5 18 0 0 4 0 1 1 0 1 0 13
2022/2023141 6 15 5 57 11 31 0 8 7 0 1 0
2023/202447 1 4 2 2 7 13 0 5 1 6 5 1
2024/2025115 7 3 7 23 2 7 3 1 20 10 12 20
2025/2026277 23 21 41 63 109 20 0 0 0 0 0 0
Totale 808